Enveric Biosciences (ENVB) Operating Expenses (2010 - 2026)
Enveric Biosciences (ENVB) posted Operating Expenses of $1.6 million for Q1 2026, down 25.56% sequentially from $2.2 million in Q4 2025, and down 25.34% YoY from $2.2 million in Q1 2025.
Enveric Biosciences (ENVB) Operating Expenses (2010 - 2026) Analysis & Trends
Enveric Biosciences has reported Operating Expenses for 17 years, with the latest figure at $1.6 million in Q1 2026.
- Quarterly Operating Expenses fell 25.34% year-over-year to $1.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.2 million (down 12.01% YoY) and the FY2025 annual result came in at $8.8 million, down 8.91% from the prior year.
- Operating Expenses fell to $1.6 million in Q1 2026 per ENVB's latest filing, from $2.2 million in the prior quarter.
- Over five years, Operating Expenses peaked at $12.3 million in Q4 2022 and troughed at $1.6 million in Q1 2026.
- A 5-year average of $3.8 million and a median of $2.5 million in 2025 frame the typical range for Operating Expenses.
- The sharpest annual moves came in 2022 and 2023: Operating Expenses surged 60.85% in 2022, then plunged 80.54% in 2023.
- Over 5 years, Operating Expenses stood at $12.3 million in 2022, then slumped by 80.54% to $2.4 million in 2023, then soared by 33.11% to $3.2 million in 2024, then sank by 30.87% to $2.2 million in 2025, then declined by 25.56% to $1.6 million in 2026.
- According to Business Quant data, Operating Expenses over the past three periods registered $1.6 million, $2.2 million, and $1.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.06 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 427.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 541.02 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -784.57 Mn |
| 10 | Enveric Biosciences | 5.42 Mn | -2.87 Mn | - | 3.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.63 Mn |
| Dec 31, 2025 | 2.19 Mn |
| Sep 30, 2025 | 1.87 Mn |
| Jun 30, 2025 | 2.52 Mn |
| Mar 31, 2025 | 2.19 Mn |
| Dec 31, 2024 | 3.17 Mn |
| Sep 30, 2024 | 2.08 Mn |
| Jun 30, 2024 | 1.90 Mn |
| Mar 31, 2024 | 2.48 Mn |
| Dec 31, 2023 | 2.38 Mn |
| Sep 30, 2023 | 3.45 Mn |
| Jun 30, 2023 | 5.76 Mn |
| Mar 31, 2023 | 4.86 Mn |
| Dec 31, 2022 | 12.26 Mn |
| Sep 30, 2022 | 5.66 Mn |
| Jun 30, 2022 | 4.71 Mn |
| Mar 31, 2022 | 4.80 Mn |
| Dec 31, 2021 | 50.98 Mn |
| Sep 30, 2021 | 3.52 Mn |
| Jun 30, 2021 | 3.36 Mn |